AzurRx BioPharma, Inc.
AZRX · NASDAQ
12/31/2024 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.13 | 0.07 | 0.09 |
| FCF Yield | -77.78% | -20.91% | -60.27% | -58.48% |
| EV / EBITDA | -0.76 | -2.00 | -1.80 | -1.41 |
| Quality | ||||
| ROIC | -26.96% | -4,321.40% | -236.97% | -284.04% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.51 | 0.34 | 0.92 | 0.80 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 0.00% | 20.14% | -28.68% | -51.38% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | -0.10 | 0.07 |
| Interest Coverage | -17,852.88 | -4.53 | -33.98 | -131.88 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |